30th Technical Meeting

To protect patients, provide safe products and minimise vein to vein time, cutting-edge cellular therapies need state-of-the-art quality control solutions.

bioMérieux’s proven portfolio of microbiology testing solutions enable sites to carry out tests throughout each stage of the production process. bioMérieux provides solutions adapted for the unique set of requirements for testing ATMP’s. Testing for final products but, also at-line and in-process controls to relieve potential process bottle necks. Helping to maintain regulatory compliance and optimize operations for the future. These include:

• BACT/ALERT 3D DUAL T: Compendial, rapid and automated sterility testing. Ideally suited for testing turbid, short shelf-life intermediates and final products and reduced vein to vein time.
• BIOFIRE MYCOPLASMA: A 1 hour test that can be performed at-line, if required. This test can be used for release testing or testing starting materials, culture media and other in-process controls.
• ENDOZYME II GO SINGLE TEST: An animal-free endotoxin test with in-build controls designed for single or low volume testing.
• 3P Solutions: This range includes irradiated plates for environmental monitoring, 3P CONNECT Software for digitalized EM campaign management in classified areas and 3P ENTERPRISE for automated incubation and reading of EM plates.
• ACCELLIX: Automated, rapid cell attribute testing using innovative flow cytometry technology

This is just a snapshot of some of our range, please come and visit our stand to learn more about these and other bioMérieux solutions.

https://www.biomerieux.com/

Eveo^® Cell Therapy Platform is a fully closed, modular solution designed to help cell therapy manufacturers accelerate therapy delivery and overcome today’s production challenges.

By combining human centric smart automation, integrated quality control, and GMP-ready raw materials, Eveo supports end-to-end workflows or individual unit operations across multiple cell therapy product types and manufacturing models – from centralized to decentralized production, from clinical manufacturing hubs to CDMO suites to commercial production facilities

Built for flexibility, usability, and commercial-scale readiness, Eveo enables true parallelization with up to eight concurrent, individually tracked and traced batches per workstation, and multiple workstations per software instance. Its compact footprint supports high throughput, with the potential to produce up to 350 batches per workstation annually in less than 6 m², while reducing capital and operational expenditure by more than 50%. With Sartorius’ bioprocessing expertise and global support, Eveo helps make cell therapy manufacturing more efficient, reproducible, and accessible.

Eveo Cell Therapy Platform

Thermo Fisher Scientific supports cell and gene therapy developers across the journey from discovery and process development through clinical and commercial manufacturing. Its integrated capabilities combine Gibco™ Cell Therapy Systems (CTS™) products, bioprocessing technologies, analytical solutions, CDMO services, and global supply-chain expertise.

Key capabilities include autologous and allogeneic cell therapy process development and cGMP manufacturing, supported by closed and scalable technologies for cell isolation, expansion, engineering, and processing. The CTS portfolio includes GMP-manufactured media and reagents, automated cell-processing technologies, scalable electroporation, and viral-vector production solutions designed to facilitate translation into clinical and commercial manufacturing.

For gene therapy and gene-modified cell therapies, Thermo Fisher provides solutions spanning plasmid DNA, AAV and lentiviral vector production, downstream purification and characterization, together with CDMO capabilities covering process development, analytical testing, cGMP manufacturing, and sterile fill/finish. Thermo Fisher materials describe viral-vector manufacturing experience across AAV, lentivirus, adenovirus, HSV, and retrovirus, with manufacturing scales up to 2,000 L.

These capabilities are complemented by ultracold and cryogenic logistics, chain-of-custody and identity solutions, clinical supply services, and global pharmaceutical-services infrastructure, providing an integrated pathway from development through commercialization.

thermofisher.com/uk/en/home/clinical/cell-gene-therapy

Cytiva partners with biopharmaceutical, biotechnology, academic, and healthcare organizations to accelerate the development, scale-up, and commercialization of advanced therapies.

In cell therapy, Cytiva provides integrated technologies, automation solutions, and deep application expertise to support customers from early process development through commercial manufacturing. Its portfolio addresses critical manufacturing steps including cell isolation, activation, genetic modification, expansion, harvest, formulation, and cryopreservation.

The Sefia™ platform is Cytiva’s integrated solution for automated, closed manufacturing of autologous cell therapies. By bringing critical cell processing steps into a streamlined workflow, Sefia helps improve reproducibility, reduce hands-on time, and support manufacturing scale-out from clinical development to commercial production.

To address specific workflow requirements, Cytiva’s broader cell therapy portfolio provides complementary capabilities through Sepax™ cell processing technologies for automated cell handling and washing, Xuri™ cell expansion systems for cell culture and expansion, and Chronicle™ software for digital workflow management and automation. Together, these solutions help therapy developers build efficient, connected, and scalable manufacturing processes while reducing operational complexity.

eBook: Navigating cell therapy process development

Infographic: COGs process economics for autologous cell therapy

eBook: Mastering TIL therapy manufacturing

cytiva.com

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy.

Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering.

In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

www.miltenyibiotec.com/